| Platelet transfusion refractoriness and anti‐HLA immunization L Blandin, A Dougé, A Fayard, JO Bay, G Berlie, B Pereira, R Lemal, ... Transfusion 61 (6), 1700-1704, 2021 | 13 | 2021 |
| MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells S Bottardi, R Guieze, V Bourgoin, N Fotouhi-Ardakani, A Dougé, ... Experimental Hematology 88, 68-82. e5, 2020 | 11 | 2020 |
| Rationnel et modalités de prescription de l’ibrutinib dans les hémopathies lymphoïdes B A Dougé, A Ravinet, JO Bay, O Tournilhac, R Guièze, R Lemal Bulletin du Cancer 103 (2), 127-137, 2016 | 5 | 2016 |
| Intestinal microbiota and allogeneic stem cell transplantation A Dougé, JO Bay, A Ravinet, J Scanzi Bulletin du Cancer 107 (1), 72-83, 2019 | 4 | 2019 |
| Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: A study protocol for a randomised … A Dougé, A Ravinet, A Corriger, A Cabrespine, M Wasiak, B Pereira, ... BMJ open 13 (5), e068480, 2023 | 3 | 2023 |
| Pomalidomide dans les myélomes multiples A Dougé, R Lemal, C Chaleteix Bulletin du Cancer 104 (9), 707-713, 2017 | 3 | 2017 |
| Pomalidomide for multiple myeloma A Dougé, R Lemal, C Chaleteix Bulletin du Cancer 104 (9), 707-713, 2017 | 3 | 2017 |
| Microbiote intestinal et allogreffe de cellules souches hématopoïétiques A Dougé, JO Bay, A Ravinet, J Scanzi Bulletin du Cancer 107 (1), 72-83, 2020 | 2 | 2020 |
| Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia. S Bahashwan, C Moluçon-Chabrot, E Hermet, A Ravinet, A Douge, ... American Journal of Hematology 94 (1), E32-E35, 2018 | 2 | 2018 |
| The CAR-T cells are here C Croizier, A Douge, JO Bay, R Lemal Bulletin du Cancer 105 (9), 743-745, 2018 | 2 | 2018 |
| Adoptive T Cell Therapy in Solid Tumors: State-of-the Art, Current Challenges, and Upcoming Improvements A Dougé, N El Ghazzi, R Lemal, P Rouzaire Molecular Cancer Therapeutics 23 (3), 272-284, 2024 | 1 | 2024 |
| CAR-T cells development in solid tumors N El Ghazzi, A Italiano, JO Bay, A Dougé Bulletin du Cancer, S0007-4551 (22) 00436, 2022 | 1 | 2022 |
| Les CAR-T cells sont là! C Croizier, A Douge, JO Bay, R Lemal Bulletin du Cancer 105 (9), 743-745, 2018 | 1 | 2018 |
| The circulating PD-L1: An emerging predictive biomarker for immune checkpoint inhibitors response F Chovet, AS Passot, Q Mangon, P Rouzaire, A Dougé Bulletin du Cancer, S0007-4551 (24) 00048, 2024 | | 2024 |
| Le taux circulant de PD-L1: un biomarqueur émergent de réponse aux inhibiteurs de checkpoints immunitaires F Chovet, AS Passot, Q Mangon, P Rouzaire, A Dougé Bulletin du Cancer, 2024 | | 2024 |
| Prevalence of FGF23 elevation in patients with hypophosphatemia C Oris, A Lautrette, A Dougé, F Bouraima, S Kahouadji, ME Pickering, ... Clinica Chimica Acta 554, 117782, 2024 | | 2024 |
| La thérapie cellulaire dans tous ses états A Dougé, C Caux, JO Bay Bulletin du Cancer, 2024 | | 2024 |
| Cell therapy in all its forms A Dougé, C Caux, JO Bay Bulletin du Cancer, S0007-4551 (24) 00005, 2024 | | 2024 |
| Temporal regulation of transgene expression controlled by amino acid availability in human T cells A Dougé, C Vituret, V Carraro, L Parry, C Coudy‐Gandilhon, R Lemal, ... HLA 103 (1), e15252, 2024 | | 2024 |
| NUTRIREG-T cells: a nutrition-based regulatory system of transgene expression in human T cells. A Dougé, A Bruhat, PO Rouzaire FITC-ACT Workshop, co-organized with Institut Carnot CALYM. Current topics …, 2023 | | 2023 |
